Abstract: In some aspects, the present invention provides methods and compositions for modifying target sites within nucleic acid molecules. In some embodiments, the methods comprise using adenosine deaminases that act on RNA (ADARs), and variants thereof, to modify target sites within DNA-RNA hybrid molecules. In other aspects, ADAR2 variant polypeptides as well as fusion proteins comprising an ADAR catalytic domain and a hybrid nucleic acid binding domain are provided, as are methods for use thereof. Methods for preventing and treating genetic disorders are also provided herein.

Abstract: In some aspects, the present invention provides methods and compositions for modifying target sites within nucleic acid molecules. In some embodiments, the methods comprise using adenosine deaminases that act on RNA (ADARs), and variants thereof, to modify target sites within DNA-RNA hybrid molecules. In other aspects, ADAR2 variant polypeptides as well as fusion proteins comprising an ADAR catalytic domain and a hybrid nucleic acid binding domain are provided, as are methods for use thereof. Methods for preventing and treating genetic disorders are also provided herein.

Abstract: The invention relates to single-stranded RNA editing antisense oligonucleotides (AO Ns) for binding to a target RNA molecule for deaminating at least one target adenosine present in the target RNA molecule and recruiting, in a cell, preferably a human cell, an ADAR2 enzyme, to deaminate the at least one target adenosine in the target RNA molecule. The AON according to the invention comprises a cytidine analog at the position opposite the target adenosine, wherein the cytidine analog serves as an H-bond donor at the N3 site, for more efficient RNA editing.

Abstract: In some aspects, the present invention provides methods and compositions for modifying target sites within nucleic acid molecules. In some embodiments, the methods comprise using adenosine deaminases that act on RNA (ADARs), and variants thereof, to modify target sites within DNA-RNA hybrid molecules. In other aspects, ADAR2 variant polypeptides as well as fusion proteins comprising an ADAR catalytic domain and a hybrid nucleic acid binding domain are provided, as are methods for use thereof. Methods for preventing and treating genetic disorders are also provided herein.

Abstract: In some aspects, the present invention provides methods and compositions for modifying target sites within nucleic acid molecules. In some embodiments, the methods comprise using adenosine deaminases that act on RNA (ADARs), and variants thereof, to modify target sites within DNA-RNA hybrid molecules. In other aspects, ADAR2 variant polypeptides as well as fusion proteins comprising an ADAR catalytic domain and a hybrid nucleic acid binding domain are provided, as are methods for use thereof. Methods for preventing and treating genetic disorders are also provided herein.

Abstract: Disclosed are compositions and methods related to modified nucleobases. Also disclosed are compositions and methods related to modified interfering RNAs. Also disclosed are compositions and methods related to modified guanine bases for controlling off-target effects in RNA interference.

Abstract: A method for selecting an active router in a communication device includes providing multiple routers in the device, coupling the routers to a single physical link, monitoring a status for each of the routers, and selecting one of the routers as an active router by positioning its corresponding relay.

Abstract: Improved oligonucleotides and processes for their use for specific recognition of a target sequence in double-stranded nucleic acid through the formation of an alternate strand triple-helix. The triple-helix forming oligonucleotides bind in a parallel and antiparallel orientation, respectively, to target sequences on alternate strands of the double helical nucleic acid. The oligonucleotides are useful as diagnostic or therapeutic agents and can incorporate an appropriate moiety in one or more nucleotides in the triple-helix forming oligonucleotide.